ERBB2 and breast cancer: BT474 and JIMT-1 human breast cancer cells are both resistant to trastuzumab, the humanized monoclonal antibody against HER2, the human epidermal growth factor receptor 2, which is overexpressed in about 30% of breast cancers and considered a marker of poor prognosis.